Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

Unidades de investigação

• Medicina

Abstract

[No abstract available]

Keywords

• Antibodies, Monoclonal; Antibodies, Neutralizing; COVID-19; Drug Combinations; Humans; cilgavimab plus tixagevimab; placebo; remdesivir; cilgavimab; cilgavimab and tixagevimab drug combination; monoclonal antibody; neutralizing antibody; tixagevimab; cause of death; confidence interval; coronavirus disease 2019; drug safety; drug tolerability; follow up; hazard ratio; health care quality; health status; hospital patient; hospitalization; human; immune response; immunocompromised patient; immunology; Letter; mortality; oxygen supply; phase 3 clinical trial (topic); randomized controlled trial (topic); risk reduction; Severe acute respiratory syndrome coronavirus 2; unspecified side effect; vaccination; variant of concern; virus neutralization; virus resistance; virus strain; clinical trial; controlled study; coronavirus disease 2019; drug combination; phase 3 clinical trial; randomized controlled trial